This is also supported by a mouse study showing that propranolol, a β2-AR antagonist, potentiates the antitumor effects of radiotherapy in gastric cancer by inhibiting NF-κB expression and its downstream genes: VEGF, EGFR, and COX-2 [107]. The gene discussed is EGFR; the disease is gastric cancer.